コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nase inhibitors as a therapeutic strategy in Lowe syndrome.
2 ns result in a myriad of phenotypes found in Lowe syndrome.
3 ciliary dysfunction in the manifestation of Lowe syndrome.
4 raffic leads to the neurological symptoms of Lowe syndrome.
5 ous system and ocular defects in the case of Lowe syndrome.
6 cal abnormalities that are characteristic of Lowe syndrome.
7 toskeleton in fibroblasts from patients with Lowe syndrome.
8 in this activity result in the human disease Lowe syndrome.
9 ile 85% of the values are from patients with Lowe syndrome.
10 l polyphosphate 5-phosphatase, is mutated in Lowe syndrome.
11 culocerebral renal syndrome of Lowe (OCRL or Lowe syndrome), a severe X-linked congenital disorder ch
12 PIP2 in human fibroblasts from patients with Lowe syndrome, a genetic disorder that affects phosphoin
15 om kidney proximal tubules of a patient with Lowe syndrome and a normal individual were used to study
17 and are consistent with a scenario in which Lowe syndrome and Dent disease result from perturbations
18 OCRL, whose mutations are responsible for Lowe syndrome and Dent disease, and INPP5B are two simil
21 L1 leads to the phenotypic manifestations of Lowe syndrome are currently unclear, in part, owing to t
32 he gene that when mutated is responsible for Lowe syndrome, or oculocerebrorenal syndrome (OCRL), is
35 nclusion, we report novel OCRL1 mutations in Lowe syndrome patients and the corresponding histopathol
37 logical defects similar to those reported in Lowe syndrome patients, namely increased susceptibility
41 ysosomal enzyme trafficking in patients with Lowe syndrome that leads to increased extracellular lyso
43 lyphosphate 5-phosphatase that is mutated in Lowe syndrome, was investigated by fluorescence microsco
45 sitol 5-phosphatase OCRL are responsible for Lowe syndrome, whose manifestations include mental retar
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。